← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Optimum Therapeutics, Llc
Columbus, OH
$12,197,134
Total funding
14
Grants
Funding over time
peak $2.2M · FY2005–17$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
Funding mix
By agency
NIH$12,197,134 · 14
By mechanism
R01$7,010,934 · 5
R44$2,833,025 · 2
R43$2,353,175 · 7
Investigators at Optimum Therapeutics, Llc
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
Rapid release paclitaxel nanoparticles for bladder cancer intravestical therapy$730,684
R44 · FY2008 · CA
Rapid release paclitaxel nanoparticles for bladder cancer intravestical therapy$645,019
R44 · FY2009 · CA
Apoptosis Inducing to Enhance Tumor Targeting$565,979
R44 · FY2007 · CA
Tumor-priming Microparticles for Pancreatic Cancer$441,343
R44 · FY2006 · CA
Rapid release paclitaxel nanoparticles for bladder cancer intravestical therapy$400,000
R44 · FY2009 · CA
Targeting multiple signaling steps to achieve synergy$390,100
R01 · FY2017 · CA
Targeting multiple signaling steps to achieve synergy$390,100
R01 · FY2012 · CA
Targeting multiple signaling steps to achieve synergy$390,100
R01 · FY2016 · CA
Targeting multiple signaling steps to achieve synergy$378,396
R01 · FY2015 · CA
Synergistic chemo-siRNA combination therapy$372,483
R01 · FY2011 · CA
Synergistic chemo-siRNA combination therapy$372,483
R01 · FY2012 · CA
Synergistic chemo-siRNA combination therapy$372,483
R01 · FY2015 · CA
Targeting multiple signaling steps to achieve synergy$366,694
R01 · FY2013 · CA
Synergistic chemo-siRNA combination therapy$361,309
R01 · FY2014 · CA
Telomeres, telomerase and chemotherapy: Bench to bedside$352,225
R01 · FY2010 · CA
Synergistic chemo-siRNA combination therapy$350,134
R01 · FY2013 · CA
Telomeres, telomerase and chemotherapy: Bench to bedside$346,857
R01 · FY2009 · CA
Combination chemo-siRNA gene therapy of nonmuscle-invading bladder cancer$344,460
R43 · FY2012 · TR
Telomeres, telomerase and chemotherapy: Bench to bedside$338,540
R01 · FY2008 · CA
Multiscale computational models for developing combination cancer therapy$337,479
R01 · FY2014 · GM